Therapeutic potential of CDK11 in cancer
Clinical and Translational Medicine · 2023-03 · 13 (3)
DOI: 10.1002/ctm2.1201 ↗Kurz gefasst
Kommentar in der Zeitschrift Clinical and Translational Medicine, online erschienen am 28.02.2023. Verfasst von Dalibor Blazek. Beteiligte Einrichtung: Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinases, Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Czech Science Foundation.
Abstract (Originalsprache)
Human cyclin‐dependent kinases (CDKs) direct the progression of the cell cycle and transcription. They are deregulated in tumours, and despite their involvement in the regulation of basic cellular processes, many CDKs are promising targets for cancer therapy. CDK11 is an essential gene for the growth of many malignancies; however, its primary cellular function has been obscure, and the mode‐of‐action of OTS964, the first CDK11 inhibitor and antiproliferative compound, has been unknown. A recent study has shown that OTS964 prevents spliceosome activation, revealing a key role of CDK11 in the regulation of pre‐mRNA splicing. In light of these findings, we discuss the therapeutic potential of CDK11 in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
ORCID-Profile: Dalibor Blazek
Förderung
- the Czech Science Foundation
Zitieren
APA
Blazek, D. (2023). Therapeutic potential of CDK11 in cancer. Clinical and Translational Medicine, 13(3). https://doi.org/10.1002/ctm2.1201
Vancouver
Blazek D. Therapeutic potential of CDK11 in cancer. Clinical and Translational Medicine. 2023;13(3). doi:10.1002/ctm2.1201
BibTeX
@article{Blazek2023,
author = {Blazek, Dalibor},
title = {Therapeutic potential of CDK11 in cancer},
journal = {Clinical and Translational Medicine},
year = {2023},
volume = {13},
number = {3},
doi = {10.1002/ctm2.1201}
}
EUVIMED